Información de Valneva SE, dividendo de Valneva SE, actividades de los accionistas y más

Más Datos de Valneva SE Compañía

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Información de Valneva SE



Símbolo de cotizaciónVALN

Nombre de la empresaValneva SE

Fecha de salida a bolsaJun 28, 2007

Director ejecutivoLingelbach (Thomas)

Número de empleados- -

Tipo de seguridadDepository Receipt

Fin del año fiscalJun 28

Dirección6, Rue Alain Bombard

CiudadSAINT-HERBLAIN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísFrance

Código postal44800

Teléfono33228073710

Sitio Webhttps://valneva.com/

Símbolo de cotizaciónVALN

Fecha de salida a bolsaJun 28, 2007

Director ejecutivoLingelbach (Thomas)

Ejecutivos de Valneva SE



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Mr. Peter Buehler

Chief Financial Officer

--

Ms. Dipal Patel

Chief Commercial Officer

--

Mr. James Connolly

Independent Director

--

Ms. Mailys Ferrere

Director, Representative of Bpifrance Participations SA

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

IXIARO

94.07M

55.47%

Third party products

33.19M

19.57%

DUKORAL

32.30M

19.05%

Chikungunya VLA1553

3.70M

2.18%

Others

1.13M

0.67%

Unallocated

704.00K

0.42%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

48.59M

28.66%

Canada

32.32M

19.06%

United Kingdom

19.49M

11.49%

Germany

18.37M

10.84%

Austria

15.90M

9.37%

Otro

34.91M

20.58%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

IXIARO

94.07M

55.47%

Third party products

33.19M

19.57%

DUKORAL

32.30M

19.05%

Chikungunya VLA1553

3.70M

2.18%

Others

1.13M

0.67%

Unallocated

704.00K

0.42%

Estadísticas de accionistas

Actualizado: sáb., 7 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

Novo Holdings A/S

2.73%

Frazier Life Sciences Management, L.P.

2.67%

General American Investors Company, Inc.

0.41%

Wells Fargo Advisors

0.18%

Marshall Wace LLP

0.04%

Otro

93.97%

Accionistas

Proporción

Novo Holdings A/S

2.73%

Frazier Life Sciences Management, L.P.

2.67%

General American Investors Company, Inc.

0.41%

Wells Fargo Advisors

0.18%

Marshall Wace LLP

0.04%

Otro

93.97%

Tipos de accionistas

Accionistas

Proporción

Venture Capital

2.73%

Private Equity

2.67%

Investment Advisor

0.46%

Research Firm

0.22%

Investment Advisor/Hedge Fund

0.04%

Hedge Fund

0.02%

Otro

93.86%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

32

5.28M

6.15%

+519.56K

2025Q3

30

4.53M

5.58%

+3.61M

2025Q2

25

665.50K

0.82%

-300.83K

2025Q1

28

666.20K

0.82%

-333.59K

2024Q4

27

820.97K

1.18%

-47.15K

2024Q3

26

836.06K

1.21%

+31.78K

2024Q2

28

742.08K

1.07%

+162.52K

2024Q1

32

513.10K

0.74%

-47.53K

2023Q4

30

421.64K

0.61%

-110.65K

2023Q3

32

418.35K

0.60%

-285.66K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Novo Holdings A/S

2.35M

2.73%

-30.00K

-1.26%

Sep 30, 2025

Frazier Life Sciences Management, L.P.

2.29M

2.67%

+833.33K

+57.14%

Sep 30, 2025

General American Investors Company, Inc.

354.36K

0.41%

--

Sep 30, 2025

Wells Fargo Advisors

153.99K

0.18%

-91.19K

-37.19%

Sep 30, 2025

Marshall Wace LLP

31.21K

0.04%

+31.21K

--

Sep 30, 2025

Ironwood Investment Management, LLC

25.14K

0.03%

--

Sep 30, 2025

Morgan Stanley & Co. International Plc

22.77K

0.03%

+16.23K

+248.03%

Sep 30, 2025

Citadel Advisors LLC

16.41K

0.02%

-19.33K

-54.08%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

10.20K

0.01%

+8.72K

+589.93%

Sep 30, 2025

J.P. Morgan Securities LLC

10.18K

0.01%

+10.18K

--

Sep 30, 2025

ETFs relacionados



Nombre

Proporción

Sin datos

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos